Background: Intestinal barrier dysfunction plays a central role in the pathological onset of Crohn’s disease. We identify the cadherin superfamily member protocadherin 20 (PCDH20) as a crucial factor in Crohn’s disease. Here we describe the function of PCDH20 and its mechanisms in gut homeostasis, barrier integrity, and Crohn’s disease development.Results: PCDH20 mRNA and protein expression is significantly downregulated in the colonic epithelium of Crohn’s disease patients and mice with induced colitis compared with controls. In mice, intestinal-specificPcdh20knockout causes defects in enterocyte proliferation and differentiation, while causing morphological abnormalities. Specifically, the deletion disrupts barrier integrity by unzipping adherens junctions via β-catenin regulation and p120-catenin phosphorylation, thus aggravating colitis in DSS- and TNBS-induced colitis mouse models. Furthermore, we identify activating transcription factor 6 (ATF6), a key chaperone of endoplasmic reticulum stress, as a functional downstream effector of PCDH20. By administering a selective ATF6 activator, the impairment of intestinal barrier integrity and dysregulation of CHOP/β-catenin/p-p120-catenin pathway was reversed inPcdh20-ablated mice with colitis andPCDH20-deficient colonic cell lines.Conclusions: PCDH20 is an essential factor in maintaining intestinal epithelial homeostasis and barrier integrity. Specifically, PCDH20 helps to protect against colitis by tightening adherens junctions through the ATF6/CHOP/β-catenin/p-p120-catenin axis.
In this note we analyze the problems in the nucleic acid testing (NAT) of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), and we also give some suggestions for improving the accuracy of NAT diagnosis. NAT testing is considered to be the diagnostic “gold standard”; at present there are few reviews on NAT for SARS-CoV-2. Moreover, many false-negative results always appear in the procedure of detecting, which has affected early diagnosis of the disease and brought a great challenge to mitigation and containment of the pandemic. In conclusion, comprehensive analyses of serological and imaging findings should be performed to guide the formulation of an accurate clinical diagnosis, treatment plan, and monitoring therapeutic efficacy, in an effort to achieve early diagnosis, containment, and treatment of the disease, thereby effectively reducing progression of the pandemic. This article presents a literature overview of SARS-CoV-2 nucleic acid testing, aiming to provide support for clinicians.
Background: This paper aimed to assess the prevalence of human papillomavirus (HPV) infection and the associations of sociodemographic and behavioral characteristics with HPV in unvaccinated men in Henan Province before the mass administration of the HPV vaccine through a baseline survey.Methods: Between June 2015 to June 2020, 3,690 men were tested for the HPV genotype at the Henan Provincial People's Hospital. The HPV genotype was detected by a polymerase chain reaction (PCR)-based hybridization gene chip assay.Results: The overall HPV infection rate was 29.97%; The most prevalent genotypes were HPV 6 (21.76%), 11 (12.68%), 16 (8.94%), 58 (5.37%), 18 (3.41%), 84 (3.25%), 61 (3.09%), and 81 (3.09%). Low-risk HPV (LR-HPV) infection (24.91%) and single infection (17.78%) were the most prevalent forms. Age-specific HPV distribution was presented as a bimodal curve; the youngest age group (≤ 25 years) had the highest HPV infection rate (36.03%), followed by the 36–40-year-old group (33.68%). Men with Junior high school or above were more likely to have Pure-LR HPV infection. Unmarried status and smoking increased single and LR-HPV infection. Multiple lifetime sex partners and not using a condom were more likely to cause LR-HPV infection.Conclusions: The data on the prevalence and HPV infection type distribution in men in Henan Province could serve as a valuable reference to guide nationwide screening. We provide a time-based estimate of the maximum impact of the HPV vaccine and critical reference measurements important for assessing the clinical benefits of HPV vaccination and the increase in non-vaccine HPV types.
Introduction: The long-term immunogenicity, adverse effects, influencing factors, and protection from booster vaccines remain unclear. Specifically, little is known regarding the humoral immunity and breakthrough infections associated with COVID-19 booster immunization. Therefore, we evaluated the immunogenicity, reactogenicity, influencing factors, and protective effects of the first coronavirus disease booster vaccine 23 months before and after implementation of dynamic zero epidemic control measures among healthcare staff.Methods: We prospectively included 389 healthcare staff members in China with negative pre-enrolment severe acute respiratory syndrome coronavirus 2 test results. Neutralising serum antibodies were evaluated every two months till 23 months post-booster vaccination. Breakthrough infection was recorded or confirmed by SARS-CoV-2 specific PCR testing via throat swabs from participants before and after dynamic zero epidemic control measures.Results: At 15–30 days after vaccination, the mean concentration of the booster vaccine was 6.4 times above initial concentrations. Poorer antibody responses by booster vaccine correlated with male sex, longer post-booster duration, same-manufacturer vaccines, post-routine epidemic control measures implementation and intervals >210 days between primary and booster vaccinations. Higher breakthrough rates were associated with longer post-booster durations and post-routine epidemic control measures implementation but not associated with levels of neutralising antibodies after booster vaccination from participants. Adverse reactions were non-serious. These booster vaccine doses induced rapid, robust antibody responses, maintained for only 6–7 months.Discussion: Neutralizing antibodies induced by breakthrough infection with SARS-CoV-2 were weaker than those induced by the first COVID-19 booster vaccine, predicting that antibodies induced by SARS-CoV-2 may be very different from those of other known infectious pathogens.
The neutralisation ability of homologous and heterologous booster vaccinations against the KP.2 variant of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is unknown. Therefore, we aimed to evaluate the neutralisation of the Omicron variants by comparing serum samples from Chinese individuals who received heterologous boosters (from different manufacturers) with those who received homologous boosters (from the same manufacturer) against SARS-CoV-2. We collected serum samples from participants in the homologous (n = 38) and heterologous booster groups (n = 38) over 690 days. Serum pseudo virus neutralisation was tested against the prototype, XBB.1, JN.1, and KP.2 variants to detect neutralisation titres. An enzyme-linked immunosorbent assay was used to measure the total concentration of neutralising antibodies against the receptor binding domain of SARS-CoV-2. Neutralisation assays revealed 12.3-, 12.3-, and 11.4-fold reductions against JN.1, KP.2, and XBB.1 variants, respectively, compared with that against the prototype. However, no significant difference was observed in neutralising antibody titres among the JN.1, KP.2, and XBB.1 Omicron variants. Additionally, homologous boosters and men produced fewer neutralising antibodies compared to heterologous boosters and women. Thus, our results demonstrate that the Omicron variant KP.2 exhibits similar evasion properties to those observed in other variants.
Background Ulcerative colitis (UC) is an inflammatory bowel disease that leads to UC-associated colorectal cancer (UC-CRC), causing high mortality. Understanding UC-CRC's molecular mechanisms is vital for early diagnosis and treatment. The sensitivity and specificity of traditional tumor markers such as CEA, CA199, and CA153 are poor, establishing the need for more sensitive detection markers. Here we describe the clinical application of miR-21 and miR-223 combined with CLDN8 as new UC-CRC biomarkers. Methods The expression of CLDN8, miR-21, and miR-223 were detected by immunohistochemistry and Q-PCR. The diagnostic values of miRNAs and CLDN8 were evaluated using receiver operating characteristic curves and the area under the curve. The optimal specificity and sensitivity were according to the Youden index, (Youden index = Sensitivity + Specificity − 1). The diagnostic panels were constructed using a stepwise logistic regression model. Cell proliferation and apoptosis were measured by the CCK-8 assay and flow cytometry. Results CLDN8 was downregulated in the tissues of UC-CRC, and the expression of miR-21 and miR-223 both in the serum and intestinal mucosa tissues of patients with UC-CRC was higher compared with that of the control group. miR-21 and miR-223 combined with CLDN8 as a molecular marker of UC-related CRC are superior to traditional tumor markers. Corresponding changes occurred in downstream signaling pathway proteins related to CLDN8 and epithelial-to-mesenchymal transition (EMT) after miR-21 and miR-223 transfection. Conclusion miR-21 and miR-223 can destroy tight junctions between intestinal epithelial cells by targeting CLDN8 and promoting the occurrence and development of UC-CRC through EMT. Therefore, the combination of serum miR-21 and miR-223 and tissue CLDN8 detection is expected to become a new biomarker for early diagnosis and prognostic monitoring of UC-CRC.